耐药结核病新疗法的仿制药价格估算
该研究基于原料药每公斤价格、合成路线与制剂成本等,估算贝达喹啉、德拉马尼、普托马尼、利奈唑胺等抗耐药结核药物的仿制药价格。估算仿制药价格较当前最低可得价格低87%-98%,含普托马尼的三药方案每疗程53-276美元。竞争性大规模仿制药生产可在现有采购预算内治疗5-10倍MDR-TB病例。
要点
- 贝达喹啉、德拉马尼、利奈唑胺仿制药价较当前最低价低87%-98%。
- 含普托马尼三药方案估算每疗程53-276美元。
- 大规模竞争性仿制药生产可扩大MDR-TB治疗覆盖5-10倍。
核心结论
- 竞争性大规模仿制药生产可在现有采购预算内提供5-10倍MDR-TB病例的治疗。
研究设计与样本
- 基于原料药每公斤价格、制剂与包装成本及利润率估算利奈唑胺、莫西沙星和氯法齐明的仿制药价格。
- 基于化学相似性将舒特唑胺成本估算为与利奈唑胺相当。
- 通过评估合成路线、化学试剂每公斤成本及每步产率估算贝达喹啉、德拉马尼和普托马尼的仿制药价格。
- 成本算法反映不同监管要求和基于需求的规模效率,并用广泛可及的结核药物验证预测能力。
主要发现
- 估算仿制药价格:贝达喹啉每月8-17美元,德拉马尼每月5-16美元,普托马尼每月11-34美元。
- 估算仿制药价格:利奈唑胺每月4-9美元,舒特唑胺每月4-9美元,氯法齐明每月4-11美元,莫西沙星每月4-8美元。
- 仿制药估算价格较当前最低可得价格低:贝达喹啉87%-94%,德拉马尼95%-98%,利奈唑胺94%-97%。
- STREAM试验改良孟加拉方案估算每疗程168-395美元(当前成本734-1799美元)。
- 含普托马尼三药方案估算每疗程53-276美元,含德拉马尼四药方案估算每疗程238-507美元。
关键数值与推荐
- 全球MDR-TB年发病率估计480 000例,占结核发病5%,但占死亡20%。
- 当前MDR-TB每疗程治疗费用达数千美元。
临床怎么用
- 仿制药价格估算可为MDR-TB治疗方案的可负担性与采购预算规划提供参考。
- 在现有采购预算内,大规模仿制药生产有望使治疗覆盖的MDR-TB病例数扩大5-10倍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The estimated worldwide annual incidence of MDR-TB is 480 000, representing 5% of TB incidence, but 20% of mortality. Multiple drugs have recently been developed or repurposed for the treatment of MDR-TB. Currently, treatment for MDR-TB costs thousands of dollars per course. OBJECTIVES: To estimate generic prices for novel TB drugs that would be achievable given large-scale competitive manufacture. METHODS: Prices for linezolid, moxifloxacin and clofazimine were estimated based on per-kilogram prices of the active pharmaceutical ingredient (API). Other costs were added, including formulation, packaging and a profit margin. The projected costs for sutezolid were estimated to be equivalent to those for linezolid, based on chemical similarity. Generic prices for bedaquiline, delamanid and pretomanid were estimated by assessing routes of synthesis, costs/kg of chemical reagents, routes of synthesis and per-step yields. Costing algorithms reflected variable regulatory requirements and efficiency of scale based on demand, and were validated by testing predictive ability against widely available TB medicines. RESULTS: Estimated generic prices were US$8-$17/month for bedaquiline, $5-$16/month for delamanid, $11-$34/month for pretomanid, $4-$9/month for linezolid, $4-$9/month for sutezolid, $4-$11/month for clofazimine and $4-$8/month for moxifloxacin. The estimated generic prices were 87%-94% lower than the current lowest available prices for bedaquiline, 95%-98% for delamanid and 94%-97% for linezolid. Estimated generic prices were $168-$395 per course for the STREAM trial modified Bangladesh regimens (current costs $734-$1799), $53-$276 for pretomanid-based three-drug regimens and $238-$507 for a delamanid-based four-drug regimen. CONCLUSIONS: Competitive large-scale generic manufacture could allow supplies of treatment for 5-10 times more MDR-TB cases within current procurement budgets.
引用
- Gotham D, Fortunak J, Pozniak A, et al. Estimated generic prices for novel treatments for drug-resistant tuberculosis. J Antimicrob Chemother. 2017. PMID: 28073970. doi:10.1093/jac/dkw522
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。